

Request for proposal (RFP)



For purchase of reagents for research purposes

Project “Development of first-in-class antibody therapy for treatment of the ultra-rare LABD indication as well as for pulmonary and autoimmune diseases with IgA mediated pathology, using Companion Diagnostics (CDx) patient stratification for treatment with the JJP-1212”,

financed by the Medical Research Agency (Poland)

Number of RFP: 2401_T01_DLY_04

JJP Biologics
Bobrowiecka 6,
00-728, Warsaw,
Poland

Company and scientific background

JJP Biologics is a newly established Polish biotechnological company focused in the areas of autoimmune diseases and cancer.

Autoantibodies have been reported to be involved in the pathogenesis of many autoimmune and inflammatory disease indications. Especially autoantibodies from the IgA isotype are reported to correlate closely with disease severity. Moreover, IgA antibodies have potent effector functions that promote the IgA autoantibodies from just a biomarker to pathological effector molecule that drive the disease in autoantigen IgA positive patients.

First-into-Human indication is Linear IgA Bullous Disease (LABD) and these LABD patients have IgA autoantibodies and massive accumulation of activated neutrophils in the skin. These IgA autoantibodies in LABD are directed against collagen type XVII, which is an important adhesion molecule in the dermo-epidermal junction. Neutrophil (over) activation in LABD seems to be the direct result of CD89 triggered by IgA autoantibodies, which leads to skin damage and blister formation followed by skin damage.

Lead molecule and status

The desired Product is a S228P-stabilized humanized Immunoglobulin G4 (IgG4) monoclonal antibody, which binds to CD89 (the IgA receptor or FcαR) expressed on human neutrophils, monocytes, macrophages, and eosinophils and antagonizes IgA-mediated stimulation.

One of the components of JJP-1212' preparation for clinical studies is to develop an in vitro disease model of DH and LABD and use it to test the effectiveness of a new biological drugs.

Scope of Request for proposal

The scope of the Request for Proposal (RFP) covers the purchase and supply of reagents, according to the following specifications:

	subject / reagent*	capacity	basic order - quantity	supplementary order
part 1	IgA conjugate: Anti-human IgA (alpha chain) goat IgG fraction, fluorescein-conjugated (SKU: 0855077) MP Biomedicals	2 mL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 2	IgG conjugate: Anti-human IgG (whole molecule) goat IgG fraction, fluorescein-conjugated (SKU: 0855144) MP Biomedicals	2 mL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 3	C3 conjugate: Anti-human complement C3 goat IgG fraction, fluorescein-conjugated (SKU:0855167) MP Biomedicals	2 mL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 4	granulocyte isolation: 11191-100ML HISTOPAQUE 1119 (SKU: 11191-100ML) Sigma-Aldrich Co. LLC	100 mL	2	<i>delivery of min. 1 and max. 4 additional reagents, according to separate orders</i>
part 5	granulocyte isolation: 10771-100ML HISTOPAQUE-1077 (SKU: 10771-100ML) Sigma-Aldrich Co. LLC	100 mL	2	<i>delivery of min. 1 and max. 4 additional reagents, according to separate orders</i>
part 6	protein A: Protein A soluble from Staphylococcus aureus (SKU: 82526-5MG) Sigma-Aldrich Co. LLC	5mg	2	<i>delivery of min. 1 and max. 4 additional reagents, according to separate orders</i>
part 7	Proteinase 3/PR3 Rabbit mAb (Catalog No.: A19748) ABclonal	100 µL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 8	CD33 Antibody (Catalog No.: PA5-120758) Thermo Fisher Scientific Inc.	100 µL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 9	Invitrogen CD13 Recombinant Rabbit Monoclonal Antibody (SC70-01) (Catalog # MA5-32226) Thermo Fisher Scientific Inc.	100 µL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>



part 10	Invitrogen L5RA Polyclonal Antibody (catalog # PA5-119930) Thermo Fisher Scientific Inc.	100 µL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 11	Invitrogen CD89 Polyclonal Antibody (catalog # PA5-143971) Thermo Fisher Scientific Inc.	100 µL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 12	TRITC conjugate: Rhodamine (TRITC) Goat Anti-Rabbit IgG (H+L) (Catalog No. AS040) ABclonal	100 µL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 13	CY5v conjugate: Goat Anti-Rabbit IgG H&L (Cy5 [®]) preadsorbed (catalog # ab6564) Abcam Ltd	500µg	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 14	Dry Dyes & Certified Stains: Methylene Blue hydrate (CAS number: 122965-43-9, SKU code:66720-25G) Sigma-Aldrich Co. LLC	25g	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 15	Antibodies: Mouse Anti-CEACAM8 / CD66b Antibody (catalog # MBS2463200) Biocompare.	100 µL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 16	Antibodies: CEAcam8 Polyclonal Antibody (catalog # bs-0744R) Bioss Antibodies	100 µL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 17	Mouse IgG (whole molecule)–TRITC antibody produced in goat (SKU code: T5393-2ML) Sigma-Aldrich Co. LLC	2 mL	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 18	Rb a Hu IgG/FITC (Catalog No.: F020202-2) Altium	pcs.	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 19	Rb a Hu IgA/FITC (Catalog No.: F020402-2) Altium	pcs.	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>
part 20	Rb a Hu C3c; Complement/FITC (Catalog No.: F020102-2) Altium	pcs.	1	<i>delivery of min. 1 and max. 2 additional reagents, according to separate orders</i>

() The catalog number and manufacturer's name are indicated to guarantee the quality and compatibility (and comparability) of the results of the tests for which the ordered reagents will be used with the experiments already conducted.*

The purchaser does not allow other packaging capacities than those indicated in the description of each RFP part.

JJP allows for partial bids, provided that the partial bid shall include a minimum of one RFP part (min. one reagent in the quantity as listed above).

- JJP reserves the right to increase the order of reagents up to the sum of the quantities ordered under the basic order and the maximum number indicated under the supplementary order, in accordance with the values indicated in the table above (right of option) - applies separately to each part of the RFP.
Orders under the right of option will be carried out in the same manner as for the basic scope and at the prices proposed in the bid.
JJP will exercise the right of option as dictated by the course of the study, under orders that may be placed at various dates and quantities until 31.12.2024
JJP reserves the right not to exercise the right of option.
- The scope of each part of the RFP includes deliveries to JJP Biologics (Bobrowiecka 6, 00-728 Warsaw) - the cost of delivery is to be included in the price and date of the deliveries is to be included in the offer.

Requirements for the supplier (applies to each part of the order)

N/A

Schedule (for each part of RFP)

- Estimated date of ordering the basic order – January / February 2024
- Delivery of reagents will be carried out on the date indicated in the bid of the selected supplier.

Criteria of choice

Evaluation will be carried out individually for each part of the order.

The decision to conclude any work order as a result of this RFP process will be based on responses. The decision-making process will consider the ability of each supplier to fulfil JJPB's needs and requirements as outlined within this RFP.

Proposals will be assessed against the following criteria:

- 100% - proposed unit net price of the reagent

The number of points will be calculated according to the formula:

$CN/CB \cdot 100$ points.

where:

CN - among the responses that meet the requirements of the RFP, the lowest unit net price of the reagent

CB - unit net price of the reagent of the studied offer

The bid with the highest number of points will be considered the most advantageous bid, separately for each part.

Deadline for the bid submission

Deadline for submission of the offer is **07.02.2024**

=> Proposal should be sent in a non-editable version (pdf)

=> date of the deliveries is to be included in the offer

Remuneration

A bidder may submit one bid for one or more parts of the subject of the RFP.

Please provide a unit price offer for the respective part of the order in Euros or Zloty*.

** If bidders' prices are given in one currency, the prices indicated by bidders will be used for comparison. If the prices are given both in PLN and in Euro, the prices converted into PLN at the exchange rate on the last day of submitting offers will be used for price comparison.*

JJP stipulates that:

- it has the right not to select any of the submitted bids;
 - has the right to cancel the proceedings in whole or in part at any time without giving any reason;
 - may select a supplier only for one or more parts of the contract,
- whereby the bidder shall not be entitled to any claims against JJP Biologics on the above grounds. (The selection of the most advantageous bid does not imply an obligation on the part of JJP to conclude a contract with the supplier).

Contact

Questions regarding the inquiry as well as the offer, please send to zapytaniabadania@jjpbiologics.com

=> Please submit RFP questions, if any, no later than 2 days before the deadline for submission of offers.